Nurse-led clinics for strict hypertension control are effective long term: A 7 year follow-up study

Diabetic Medicine

Volumn 27, Issue 8, 2010, Pages 933-937

  Woodward, A ^a   Wallymahmed, M ^a   Wilding, J P ^a   Gill, G V ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

blood pressure control; hypertension; nurse led clinic; type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NURSE;

AGED; AMBULATORY CARE FACILITIES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE;

EID: 77954803238     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03039.x     Document Type: Article

References (16)

1. Stamler J, Vaccaro O, Neaton J, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444. (Pubitemid 23046633)
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998 317 : 703 713.
3. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med 2003 348 : 383 393. (Pubitemid 36159355)
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008 358 : 580 591.
5. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N Engl J Med 2008 358 : 1565 1576.
6. Protocol Based Care Evaluation project: Report for the National Co-ordinating centre for R & D (NCCSDO) SDO/78/2004.
7. Woodward A, Wallymahmed M, Wilding J, Gill G. Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. Diabet Med 2006 23 : 780 787.
8. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter J et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999 13 : 569 592.
9. Wood D, Durrington PN, Poulter N, McInnes G, Rees A, Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998 80 : S1 S29.
10. Graves JW, Tibor M, Murtagh B, Klein L, Sheps SG. The Accoson Greenlight 300TM, the first non-automated mercury free blood pressure device to pass the international protocol for blood pressure measuring devices in adults. Blood Press Monit 2003 9 : 13 17.
11. Williams B, Poulter NR, Brown MJ, Davies M, McInnes GT, Potter JF et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society BHS-1V. J Hum Hypertens 2004 18 : 139 185.
12. Joint British Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 91 (Suppl V v1 v52.
13. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update).
14. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes; a randomised placebo controlled trial. Lancet 2003 361 : 2005 2016.
15. Colhourn H, Betteridge DJ, Durrington PN, Hitman G, Neil HW, Livingstone S et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atrovastatin Diabetes Study (CARDS): multi-centre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
16. Gutschi LM, Malcolm JC, Favreau CM, Ooi TC. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006 40 : 1672 1676.